Loading…
Survey Result for E-labeling Initiatives in Asia
Under the COVID-19 pandemic, various electronic labeling initiatives have accelerated worldwide in the healthcare and pharmaceutical fields as part of a wider digital transformation [ 1 , 2 ]. Although there is no universal definition of electronic labeling (e-labeling) globally, it is widely unders...
Saved in:
Published in: | Therapeutic innovation & regulatory science 2023-03, Vol.57 (2), p.251-260 |
---|---|
Main Authors: | , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c355t-8a0ee3b9881c105e29ba513523c18329811b96da8e326fe7a255e0ffe5ba2c63 |
container_end_page | 260 |
container_issue | 2 |
container_start_page | 251 |
container_title | Therapeutic innovation & regulatory science |
container_volume | 57 |
creator | Matsui, Rie Yamaguchi, Koji Lee, Jadz Jevz Venzon Ting, Ivy Khairilisani, Destita Chang, Jenny Seo, Jeong-Min Park, Ina Chee, Alice Seat Mee Quizon, Paul Marvin Harnpramukkul, Usanee Sem, Ellen Nguyen, Thuy Padhye, Anagha Mo, Runyi |
description | Under the COVID-19 pandemic, various electronic labeling initiatives have accelerated worldwide in the healthcare and pharmaceutical fields as part of a wider digital transformation [
1
,
2
]. Although there is no universal definition of electronic labeling (e-labeling) globally, it is widely understood that e-labeling refers to the product information that is distributed via electronic means. There are 5 factors to be considered in e-labeling, and these are discussed in this publication. APAC is an industry-driven initiative with 13 R&D-based pharmaceutical associations joining from 11 markets in Asia. e-labeling was discussed as a new topic starting in 2020, and a 22-question survey was conducted in November 2021 to understand the current e-labeling status. The survey results showed that e-labeling initiatives were at different levels of maturity in the Asian region, although most markets have started to discuss e-labeling initiatives. Various challenges exist around e-labeling initiatives due to a variety of different approaches being taken in the region. It would be advisable to develop regional guidance on how to proceed with e-labeling initiatives in the Asian region to have a consistent and efficient approach. The close collaboration between agencies, Health Care Professionals (HCPs), patients, and industry associations is important to move e-labeling initiatives forward in Asia. |
doi_str_mv | 10.1007/s43441-022-00462-5 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9549856</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2774230706</sourcerecordid><originalsourceid>FETCH-LOGICAL-c355t-8a0ee3b9881c105e29ba513523c18329811b96da8e326fe7a255e0ffe5ba2c63</originalsourceid><addsrcrecordid>eNp9kU1LxDAQhoMorqz-AQ9S8OKlOpkkbXoRRNYPEAT1HtLudI10W03ahf33Zl3Xr4NzycC882ReXsYOOZxygPwsSCElTwExBZAZpmqL7SHPdCo1yO1NnxcwYgchvECsQqsc9S4biQy5AtR7DB4Hv6Bl8kBhaPqk7nwySRtbUuPaWXLbut7Z3i0oJK5NLoKz-2yntk2gg893zJ6uJk-XN-nd_fXt5cVdWgml-lRbIBJloTWvOCjCorSKC4Wi4lpgoTkvi2xqNQnMasotKkVQ16RKi1Umxux8jX0dyjlNK2p7bxvz6t3c-qXprDO_J617NrNuYQolo80V4OQT4Lu3gUJv5i5U1DS2pW4IBnMUUisVLxqz4z_Sl27wbXQXVblEATmsgLhWVb4LwVP9dQwHs4rErCMxMRLzEYlRcenop42vlU0AUSDWghBH7Yz899__YN8B_iyVKw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2774230706</pqid></control><display><type>article</type><title>Survey Result for E-labeling Initiatives in Asia</title><source>Springer Nature</source><creator>Matsui, Rie ; Yamaguchi, Koji ; Lee, Jadz Jevz Venzon ; Ting, Ivy ; Khairilisani, Destita ; Chang, Jenny ; Seo, Jeong-Min ; Park, Ina ; Chee, Alice Seat Mee ; Quizon, Paul Marvin ; Harnpramukkul, Usanee ; Sem, Ellen ; Nguyen, Thuy ; Padhye, Anagha ; Mo, Runyi</creator><creatorcontrib>Matsui, Rie ; Yamaguchi, Koji ; Lee, Jadz Jevz Venzon ; Ting, Ivy ; Khairilisani, Destita ; Chang, Jenny ; Seo, Jeong-Min ; Park, Ina ; Chee, Alice Seat Mee ; Quizon, Paul Marvin ; Harnpramukkul, Usanee ; Sem, Ellen ; Nguyen, Thuy ; Padhye, Anagha ; Mo, Runyi</creatorcontrib><description>Under the COVID-19 pandemic, various electronic labeling initiatives have accelerated worldwide in the healthcare and pharmaceutical fields as part of a wider digital transformation [
1
,
2
]. Although there is no universal definition of electronic labeling (e-labeling) globally, it is widely understood that e-labeling refers to the product information that is distributed via electronic means. There are 5 factors to be considered in e-labeling, and these are discussed in this publication. APAC is an industry-driven initiative with 13 R&D-based pharmaceutical associations joining from 11 markets in Asia. e-labeling was discussed as a new topic starting in 2020, and a 22-question survey was conducted in November 2021 to understand the current e-labeling status. The survey results showed that e-labeling initiatives were at different levels of maturity in the Asian region, although most markets have started to discuss e-labeling initiatives. Various challenges exist around e-labeling initiatives due to a variety of different approaches being taken in the region. It would be advisable to develop regional guidance on how to proceed with e-labeling initiatives in the Asian region to have a consistent and efficient approach. The close collaboration between agencies, Health Care Professionals (HCPs), patients, and industry associations is important to move e-labeling initiatives forward in Asia.</description><identifier>ISSN: 2168-4790</identifier><identifier>EISSN: 2168-4804</identifier><identifier>DOI: 10.1007/s43441-022-00462-5</identifier><identifier>PMID: 36215028</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Asia ; COVID-19 ; Digital transformation ; Drug Safety and Pharmacovigilance ; Health care ; Health Personnel ; Humans ; Labeling ; Medical electronics ; Medicine ; Original Research ; Pandemics ; Pharmaceutical Preparations ; Pharmaceuticals ; Pharmacotherapy ; Pharmacy ; Product information ; Regional development ; Surveys</subject><ispartof>Therapeutic innovation & regulatory science, 2023-03, Vol.57 (2), p.251-260</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c355t-8a0ee3b9881c105e29ba513523c18329811b96da8e326fe7a255e0ffe5ba2c63</cites><orcidid>0000-0001-7975-1947</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36215028$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matsui, Rie</creatorcontrib><creatorcontrib>Yamaguchi, Koji</creatorcontrib><creatorcontrib>Lee, Jadz Jevz Venzon</creatorcontrib><creatorcontrib>Ting, Ivy</creatorcontrib><creatorcontrib>Khairilisani, Destita</creatorcontrib><creatorcontrib>Chang, Jenny</creatorcontrib><creatorcontrib>Seo, Jeong-Min</creatorcontrib><creatorcontrib>Park, Ina</creatorcontrib><creatorcontrib>Chee, Alice Seat Mee</creatorcontrib><creatorcontrib>Quizon, Paul Marvin</creatorcontrib><creatorcontrib>Harnpramukkul, Usanee</creatorcontrib><creatorcontrib>Sem, Ellen</creatorcontrib><creatorcontrib>Nguyen, Thuy</creatorcontrib><creatorcontrib>Padhye, Anagha</creatorcontrib><creatorcontrib>Mo, Runyi</creatorcontrib><title>Survey Result for E-labeling Initiatives in Asia</title><title>Therapeutic innovation & regulatory science</title><addtitle>Ther Innov Regul Sci</addtitle><addtitle>Ther Innov Regul Sci</addtitle><description>Under the COVID-19 pandemic, various electronic labeling initiatives have accelerated worldwide in the healthcare and pharmaceutical fields as part of a wider digital transformation [
1
,
2
]. Although there is no universal definition of electronic labeling (e-labeling) globally, it is widely understood that e-labeling refers to the product information that is distributed via electronic means. There are 5 factors to be considered in e-labeling, and these are discussed in this publication. APAC is an industry-driven initiative with 13 R&D-based pharmaceutical associations joining from 11 markets in Asia. e-labeling was discussed as a new topic starting in 2020, and a 22-question survey was conducted in November 2021 to understand the current e-labeling status. The survey results showed that e-labeling initiatives were at different levels of maturity in the Asian region, although most markets have started to discuss e-labeling initiatives. Various challenges exist around e-labeling initiatives due to a variety of different approaches being taken in the region. It would be advisable to develop regional guidance on how to proceed with e-labeling initiatives in the Asian region to have a consistent and efficient approach. The close collaboration between agencies, Health Care Professionals (HCPs), patients, and industry associations is important to move e-labeling initiatives forward in Asia.</description><subject>Asia</subject><subject>COVID-19</subject><subject>Digital transformation</subject><subject>Drug Safety and Pharmacovigilance</subject><subject>Health care</subject><subject>Health Personnel</subject><subject>Humans</subject><subject>Labeling</subject><subject>Medical electronics</subject><subject>Medicine</subject><subject>Original Research</subject><subject>Pandemics</subject><subject>Pharmaceutical Preparations</subject><subject>Pharmaceuticals</subject><subject>Pharmacotherapy</subject><subject>Pharmacy</subject><subject>Product information</subject><subject>Regional development</subject><subject>Surveys</subject><issn>2168-4790</issn><issn>2168-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kU1LxDAQhoMorqz-AQ9S8OKlOpkkbXoRRNYPEAT1HtLudI10W03ahf33Zl3Xr4NzycC882ReXsYOOZxygPwsSCElTwExBZAZpmqL7SHPdCo1yO1NnxcwYgchvECsQqsc9S4biQy5AtR7DB4Hv6Bl8kBhaPqk7nwySRtbUuPaWXLbut7Z3i0oJK5NLoKz-2yntk2gg893zJ6uJk-XN-nd_fXt5cVdWgml-lRbIBJloTWvOCjCorSKC4Wi4lpgoTkvi2xqNQnMasotKkVQ16RKi1Umxux8jX0dyjlNK2p7bxvz6t3c-qXprDO_J617NrNuYQolo80V4OQT4Lu3gUJv5i5U1DS2pW4IBnMUUisVLxqz4z_Sl27wbXQXVblEATmsgLhWVb4LwVP9dQwHs4rErCMxMRLzEYlRcenop42vlU0AUSDWghBH7Yz899__YN8B_iyVKw</recordid><startdate>20230301</startdate><enddate>20230301</enddate><creator>Matsui, Rie</creator><creator>Yamaguchi, Koji</creator><creator>Lee, Jadz Jevz Venzon</creator><creator>Ting, Ivy</creator><creator>Khairilisani, Destita</creator><creator>Chang, Jenny</creator><creator>Seo, Jeong-Min</creator><creator>Park, Ina</creator><creator>Chee, Alice Seat Mee</creator><creator>Quizon, Paul Marvin</creator><creator>Harnpramukkul, Usanee</creator><creator>Sem, Ellen</creator><creator>Nguyen, Thuy</creator><creator>Padhye, Anagha</creator><creator>Mo, Runyi</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7975-1947</orcidid></search><sort><creationdate>20230301</creationdate><title>Survey Result for E-labeling Initiatives in Asia</title><author>Matsui, Rie ; Yamaguchi, Koji ; Lee, Jadz Jevz Venzon ; Ting, Ivy ; Khairilisani, Destita ; Chang, Jenny ; Seo, Jeong-Min ; Park, Ina ; Chee, Alice Seat Mee ; Quizon, Paul Marvin ; Harnpramukkul, Usanee ; Sem, Ellen ; Nguyen, Thuy ; Padhye, Anagha ; Mo, Runyi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c355t-8a0ee3b9881c105e29ba513523c18329811b96da8e326fe7a255e0ffe5ba2c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Asia</topic><topic>COVID-19</topic><topic>Digital transformation</topic><topic>Drug Safety and Pharmacovigilance</topic><topic>Health care</topic><topic>Health Personnel</topic><topic>Humans</topic><topic>Labeling</topic><topic>Medical electronics</topic><topic>Medicine</topic><topic>Original Research</topic><topic>Pandemics</topic><topic>Pharmaceutical Preparations</topic><topic>Pharmaceuticals</topic><topic>Pharmacotherapy</topic><topic>Pharmacy</topic><topic>Product information</topic><topic>Regional development</topic><topic>Surveys</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matsui, Rie</creatorcontrib><creatorcontrib>Yamaguchi, Koji</creatorcontrib><creatorcontrib>Lee, Jadz Jevz Venzon</creatorcontrib><creatorcontrib>Ting, Ivy</creatorcontrib><creatorcontrib>Khairilisani, Destita</creatorcontrib><creatorcontrib>Chang, Jenny</creatorcontrib><creatorcontrib>Seo, Jeong-Min</creatorcontrib><creatorcontrib>Park, Ina</creatorcontrib><creatorcontrib>Chee, Alice Seat Mee</creatorcontrib><creatorcontrib>Quizon, Paul Marvin</creatorcontrib><creatorcontrib>Harnpramukkul, Usanee</creatorcontrib><creatorcontrib>Sem, Ellen</creatorcontrib><creatorcontrib>Nguyen, Thuy</creatorcontrib><creatorcontrib>Padhye, Anagha</creatorcontrib><creatorcontrib>Mo, Runyi</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Therapeutic innovation & regulatory science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matsui, Rie</au><au>Yamaguchi, Koji</au><au>Lee, Jadz Jevz Venzon</au><au>Ting, Ivy</au><au>Khairilisani, Destita</au><au>Chang, Jenny</au><au>Seo, Jeong-Min</au><au>Park, Ina</au><au>Chee, Alice Seat Mee</au><au>Quizon, Paul Marvin</au><au>Harnpramukkul, Usanee</au><au>Sem, Ellen</au><au>Nguyen, Thuy</au><au>Padhye, Anagha</au><au>Mo, Runyi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survey Result for E-labeling Initiatives in Asia</atitle><jtitle>Therapeutic innovation & regulatory science</jtitle><stitle>Ther Innov Regul Sci</stitle><addtitle>Ther Innov Regul Sci</addtitle><date>2023-03-01</date><risdate>2023</risdate><volume>57</volume><issue>2</issue><spage>251</spage><epage>260</epage><pages>251-260</pages><issn>2168-4790</issn><eissn>2168-4804</eissn><abstract>Under the COVID-19 pandemic, various electronic labeling initiatives have accelerated worldwide in the healthcare and pharmaceutical fields as part of a wider digital transformation [
1
,
2
]. Although there is no universal definition of electronic labeling (e-labeling) globally, it is widely understood that e-labeling refers to the product information that is distributed via electronic means. There are 5 factors to be considered in e-labeling, and these are discussed in this publication. APAC is an industry-driven initiative with 13 R&D-based pharmaceutical associations joining from 11 markets in Asia. e-labeling was discussed as a new topic starting in 2020, and a 22-question survey was conducted in November 2021 to understand the current e-labeling status. The survey results showed that e-labeling initiatives were at different levels of maturity in the Asian region, although most markets have started to discuss e-labeling initiatives. Various challenges exist around e-labeling initiatives due to a variety of different approaches being taken in the region. It would be advisable to develop regional guidance on how to proceed with e-labeling initiatives in the Asian region to have a consistent and efficient approach. The close collaboration between agencies, Health Care Professionals (HCPs), patients, and industry associations is important to move e-labeling initiatives forward in Asia.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>36215028</pmid><doi>10.1007/s43441-022-00462-5</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-7975-1947</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2168-4790 |
ispartof | Therapeutic innovation & regulatory science, 2023-03, Vol.57 (2), p.251-260 |
issn | 2168-4790 2168-4804 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9549856 |
source | Springer Nature |
subjects | Asia COVID-19 Digital transformation Drug Safety and Pharmacovigilance Health care Health Personnel Humans Labeling Medical electronics Medicine Original Research Pandemics Pharmaceutical Preparations Pharmaceuticals Pharmacotherapy Pharmacy Product information Regional development Surveys |
title | Survey Result for E-labeling Initiatives in Asia |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T22%3A15%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survey%20Result%20for%20E-labeling%20Initiatives%20in%20Asia&rft.jtitle=Therapeutic%20innovation%20&%20regulatory%20science&rft.au=Matsui,%20Rie&rft.date=2023-03-01&rft.volume=57&rft.issue=2&rft.spage=251&rft.epage=260&rft.pages=251-260&rft.issn=2168-4790&rft.eissn=2168-4804&rft_id=info:doi/10.1007/s43441-022-00462-5&rft_dat=%3Cproquest_pubme%3E2774230706%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c355t-8a0ee3b9881c105e29ba513523c18329811b96da8e326fe7a255e0ffe5ba2c63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2774230706&rft_id=info:pmid/36215028&rfr_iscdi=true |